Logo
Login

Company Executives

$ Management Team

Mr. Jack Wyszomierski

Independent Chairman of the Board

Age 68
Compensation $232.5K USD
Sex Male

Mr. Owen Hughes

Chief Executive Officer

Director

Age 49
Compensation $2.483M USD
Sex Male

Mr. Thomas Burns

Chief Financial Officer

Senior Vice President - Finance

Age 50
Compensation $2.269M USD
Sex Male

Mr. Bradley Sitko

Chief Investment Officer

Age 43
Compensation $8.560M USD
Sex Male

Board of Directors

From the proxy statement filed Mar 30, 2026
Directors
7
serving now
Independent
6 of 7
stated in the proxy
Average tenure
9.5 years
from year joined
CEO also chairs the board
No
Jack L. Wyszomierski
Director Age On board Independent Committees Other public boards 2025 pay Source
Owen Hughes
CEO
 51 Not stated Not independent None stated C4 Therapeutics Paid as CEO
Jack L. Wyszomierski
Board chair
 70 2010
16 years
 Independent None stated Exelixis, Inc., SiteOne Landscape Supply, Inc. $247,492
Heather L. Franklin
60 2021
5 years
 Independent None stated None stated $204,992
Natasha Hernday
54 2020
6 years
 Independent None stated None stated $219,492
Barbara Kosacz
68 2019
7 years
 Independent None stated LeonaBio, Inc. $203,492
Joseph M. Limber
73 2012
14 years
 Independent None stated None stated $216,131
Matthew D. Perry
53 2017
9 years
 Independent None stated None stated $212,492

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

3 disclosed in the proxy filed Mar 30, 2026
BVF
a beneficial holder of more than 5% of our Common Stock
$3.0 million
January 2026

Arranger fee of $3.0 million payable to the Company by Xeno for structuring the acquisition of Repare's common shares; BVF owned approximately 24.0% of Repare before the acquisition.

With Xeno Therapeutics, Inc. Open in proxy
BVF
a beneficial holder of more than 5% of our Common Stock
$5.9 million
October 2025

Short-term bridge loan extended by the Company to Xeno to facilitate the ESSA acquisition; repaid in October 2025. BVF owned approximately 24.7% of ESSA before the acquisition.

With Xeno Therapeutics, Inc. Open in proxy
BVF
a beneficial holder of more than 5% of our Common Stock
$3.0 million
October 2025

Arranger fee of $3.0 million paid to the Company by Xeno following the closing of the ESSA acquisition.

With Xeno Therapeutics, Inc. Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans